254 Results
Dr. Heinrich Roder, will present the company’s approach and recent results for a blood test stratifying patients for immunotherapy benefit on Thursday, March 10, at Molecular Med Tri-Conference.
Biodesix has selected Norgen Biotek to supply sample preparation products for its EML4-ALK blood test.
Biodesix to present data from three studies indicating the utility of blood-based diagnostic tests at the AACR annual meeting
Biodesix raised $22 million through the sale of series F preferred stock and other securities.
Biodesix press release: Wellmark BCBS of Iowa and South Dakota provides coverage for VeriStrat® Test
Biodesix’ Nicholas Dupuis, Ph. D, Speaking at MSACL 3rd Annual Conference
Horizon Blue Cross Blue Shield (BCBS) of New Jersey has determined that the VeriStrat® proteomic test is now considered a medically necessary benefit for members with advanced NSCLC.
Heinrich Roder will speak at the 6th International Conference on Bioinformatics and Systems Biology
Biodesix raises an additional $7 million in series F financing.
With positive coverage decisions from BCBS Florida and HCSC, 200 million Americans now have insurance coverage for VeriStrat testing.